OBJECTIVE To investigate the prevalence of brain magnetic resonance imaging (MRI) and subclinical abnormalities among asymptomatic individuals at risk for MS.
1
remains an unmet challenge. 5 We aim to examine the sequence of events leading to the onset of MS. To accomplish our long-term goal of identifying targets for prevention strategies and the optimal timing for their deployment, we launched a multicenter, prospective cohort study of first-degree relatives of people with MS, the Genes and Environment in Multiple Sclerosis (GEMS) project. 6 Within family members with MS, we showed that an aggregate estimate of MS risk (Genetic and Environmental Risk Score for Multiple Sclerosis Susceptibility [GERS MS ]) incorporating an individual's genetic burden [7] [8] [9] and environmental exposures 10, 11 informs MS risk beyond family history. Indeed, participants in the upper strata of the GERS MS distribution had the greatest probability of having clinical MS. 6 In the present study, we investigated early evidence of the disease in asymptomatic family members whose risk profiles for MS susceptibility are at the extreme ends of the spectrum. We hypothesized that neurologically asymptomatic, higherrisk individuals are more likely to manifest subtle inflammatory demyelination or neurodegeneration, the 2 cardinal pathological features of MS. Given the wide range of possible manifestations in MS, we obtained standard and quantitative clinical assessments as well as qualitative and quantitative neuroimaging measures.
Methods

Overall Study Design
The inclusion criteria for the GEMS project are (1) age between 18 and 50 years at enrollment and (2) at least 1 firstdegree family member (ie, parent, full sibling, or child) diagnosed as having MS ( Figure 1A) . The GEMS project study design, including calculation of the GERS MS for individualized risk stratification, has been described earlier 6 (eMethods in the Supplement). The institutional review boards of all participating sites (Partners HealthCare, National Institutes of Health, and University of Pittsburgh) approved the study. All participants provided written informed consent.
Study Design for Deep Phenotyping
One hundred neurologically asymptomatic GEMS study participants traveled to the National Institutes of Health between August 2012 and July 2015, from various locations across the United States, for detailed neuroimaging, laboratory, and neurological examination ( Figure 1A ). The eMethods in the Supplement describes participant selection criteria and the battery of standard and quantitative neurological evaluations, including vibration sensitivity testing with a device (Vibratron II; Physitemp Instruments, Inc), as well as optical coherence tomography and magnetic resonance imaging (MRI). Each participant completed a single study visit. Examiners (S.U.S., A.B., M.K.S., J.O., I.C.M.C., and D.S.R.) were unaware of each participant's risk score.
Statistical Analysis
For unadjusted comparison between higher-and lower-risk participants, we used χ 2 and Fisher exact tests for categorical variables, independent-sample 2-tailed t tests for continuous variables with normal distribution, and Wilcoxon rank sum tests for continuous variables with nonnormal distribution. The continuous outcomes from a vibration sensitivity testing device were analyzed using linear regression models. Analyses were performed using SAS (version 9.3; SAS Institute Inc), JMP (Pro 12.2.0; SAS Institute), or R (R Foundation 12, 13 ). The eMethods in the Supplement provides details on the omnibus test ( Figure 1B ) of the hypothesis that the χ 2 statistic calculated from a Fisher combined probability test (combining the P values of all phenotypes) was higher in the observed data than chance. The 90% and 95% CIs (corresponding to a threshold of P= .10 and P= .05) were derived empirically by randomly assigning participants to the higher-or lower-risk group and repeating the analysis 10 000 times. For phenotypes in which we took right-and left-sided measurements (eg, vibration sensitivity testing device), we used the measurement from the worse side to avoid inclusion of highly correlated phenotypes.
out attributing any potential difference primarily to the role of sex, we restricted subsequent analyses to women (among 65 women, 40 were at higher risk and 25 were at lower risk) ( e T a b l e1 Bi nt h eSupplement). In comparing the demographic characteristics and clinical history of the women, we observed a suggestion of higher body mass index (P = .046) and greater weight (P = .01) in the higher-risk group, but the difference was not statistically significant after adjusting for multiple testing. Higher-risk and lower-risk women had no difference in age, height, cigarette smoking exposure, 25-hydroxyvitamin D level, or history of infectious mononucleosis or migraine. No participant reported a history of diabetes.
Qualitative and Quantitative Neuroimaging Measures
To investigate evidence of MS on brain MRI in neurologically asymptomatic individuals ( Table 1) , we predefined the primary outcome measure of the study as the presence of T2-weighted hyperintense lesions that met the 2010 McDonald MRI criteria for dissemination in space (DIS).
14 Among the 65 women, 5 (8%) (4 at higher risk and 1 at lower risk [P = .64]) met the primary outcome, consistent with prior MRI findings of MS-type lesions in asymptomatic family members. 18, 19 We examined additional MRI measures as secondary outcomes (Table 1) . Among the 65 women, 3 (5%) met 2016 proposed consensus MRI criteria for MS diagnosis, 15 while 2 (3%) met criteria for RIS 2 and 4 (6%) exhibited single foci of leptomeningeal enhancement. 20 Fourteen participants (22% of the 65 women) (12 at higher risk and 2 at lower risk) had at least 40% of T2-weighted brain lesions with a perivenous appearance 16, 17 ; 3 of these participants also met the 2010
McDonald MRI criteria for DIS ( Figure 2) . One of those 3 women, and no other participant, also had a focal upper cervical spinal cord lesion. Therefore, a subset of the first-degree family members of people with MS harbor a variety of neuroimaging features associated with MS. After adjusting for the testing of multiple hypotheses, there was no difference between the 2 subgroups in the secondary neuroimaging outcomes, including normalized whole and regional (thalamus, total gray matter, and total white matter) brain volume and the mean upper cervical spinal cord crosssectional area (Table 1) . The optical coherence tomography analysis likewise showed no significant retinal nerve fiber layer thickness and total macular volume differences between the 2 groups.
Quantitative Neurological Measures
To investigate subtle subclinical dysfunction in neurologically asymptomatic participants, we measured the following quantitative outcomes known to correlate with physical and cognitive disability in MS: Expanded Disability Status Scale, 21 (Table 1) , as well as high-contrast and low-contrast visual acuity (eTable 2 in the Supplement). After considering the testing burden of multiple hypotheses, we did not identify differences between higher-risk and lower-risk women. However, higher-risk women were slower in completing the Timed Up and Go task, a test of motor and balance function, than lower-risk women (P = .03, adjusted for body weight). The expected P values assume a null distribution, with no difference between higher-and lower-risk participants. The corresponding dark and light gray areas indicate the extreme ranges of the quantile-quantile plots as generated by chance, at a threshold of P = .10 and P = .05, respectively. When the distribution of the observed P values for measured outcomes was taken as a whole, the overall difference between the higher-and lower-risk participants was unlikely to have occurred by chance (P = .01 by omnibus test). See the Methods section and eMethods in the Supplement for details.
Measures of Vibration Sensitivity
As part of the standard neurological examination, we observed impaired vibratory sensation in the distal lower extremities as measured by the 128-Hz tuning fork test. This clinical observation during the early phase of the study led to subsequent incorporation of 2 additional measures of vibration sensitivity into the study protocol, the Rydel-Seiffer graduated tuning fork 27, 28 and a vibration sensitivity testing device. [29] [30] [31] [32] Of the 65 women, 47 (27 at higher risk and 20 at lower risk) completed vibration testing using all 3 modalities, a subgroup that had demographic and clinical characteristics similar to the overall cohort of women (eTable 1B in the Supplement). We chose the vibration sensitivity testing device results as the primary outcome because this device provides the most objective quantitative measurement of vibration sensation in MS. [30] [31] [32] Because we measured vibration sensitivity in the left and right distal lower extremity (specifically, the great toe), we compared the vibration sensitivity threshold between higherrisk and lower-risk participants using the vibration unit value from the worse side 33 (ie, higher value) and the average value of the 2 sides. In univariate analysis, we found evidence of poorer vibration sensitivity (ie, higher threshold for perceiving vibration) in the distal lower extremity of the higher-risk women when comparing the worse side of the distal lower extremity (P =2×10 −4 ) or the average value between the 2 sides (P =2×10 −4 )( Table 2 and Figure 3 ).
Because vibration perception is under the potential influence of several factors, we included age at the time of testing and height as covariates in a multivariable analysis. Current cigarette smoking status was used to stratify participants, such that there was no current smoker among the lower-risk participants who underwent vibration sensitivity testing (eTable 1B in the Supplement). Given that the study was completed over 3 years, we further included the test date (in ordinal format) as a covariate and as a control for batch effect. In the multivariable analysis, evidence of poorer vibration sensitivity in higher-risk women persisted when comparing the worse vibration value (P = .008) and the average value (P =. 0 2 ) ( Table 2 ). We observed the same finding when current smoking status was also included in the analysis (P = .003 for worse vibration value and P = .008 for average vibration value).
We observed a consistent trend when comparing the vibration sensitivity testing device results with the other modalities, the 128-Hz tuning fork test (proportion of participants reporting duration ≤25 seconds) and the Rydel-Seiffer graduated tuning fork (median duration) (eTable 2 in the Supplement). Specifically, among the women, we found that lower threshold for vibration sensitivity by a vibration sensitivity testing device was correlated with shorter duration on the 128-Hz tuning fork test (Spearman coefficient, −0.33; P = .02); the 128-Hz tuning fork test and Rydel-Seiffer graduated tuning fork measures were also correlated (Spearman coefficient, 0.38; P = .01) (eFigure in the Supplement).
One woman who was neurologically asymptomatic at the study visit subsequently developed symptoms of tingling in the fingers and was diagnosed as having MS 14 months after enrollment into the GEMS project and 2 months after completing the National Institutes of Health study visit. This individual had the highest risk score within the entire GEMS c Comparing the lower-risk and higher-risk subgroups.
d Comparing the lower-risk and higher-risk subgroups after adjusting for age (at the time of testing), height, and testing date. Current smoking status was included in the Genetic and Environmental Risk Score for Multiple Sclerosis Susceptibility (GERS MS ), which categorized a participant as higher vs lower risk. There were no smokers in the lower-risk subgroup of women who completed the vibration sensitivity studies. 
Early Evidence of Multiple Sclerosis in High-Risk Family Members
Global Assessment of the Burden of Potential Neurological Dysfunction
Given the wide spectrum of neurological dysfunction seen in patients with MS at symptom onset, we investigated a large number of clinical and neuroimaging outcomes in this cohort of at-risk individuals (eResults and eTable 3 in the Supplement). To globally assess the burden of neurological dysfunction in these family members, we performed an omnibus test to assess for overall differences between the higher-risk and lower-risk participants when considering all of the measured outcomes, many of which have suggestive associations ( Figure 1B ). When the distribution of the observed P values for these outcomes was taken as a whole, the overall difference between the 2 groups of participants was greater than expected by chance (P = .01), as calculated with permutation tests. For a given outcome, we expect the difference between higher-and lower-risk participants to be beyond chance if the observed probability is outside the confidence interval and further to the right. This is the case for vibration sensitivity testing device measurements from the worse of the 2 sides, which is the great toe on the side with the higher vibration unit or worse vibration sensitivity. It is also the case for vibration sensitivity testing device measurement in the left and right great toes as well as the average of the 2 sides. For the vibration sensitivity testing device measurement from the worse side, we also compared the observed P value (univariate: P=.0002; multivariable: P=.008) to the set of minimum P values, as taken across all measured outcomes, generated from the 10 000 randomly sampled permutations (10 000 minimum P values), and found an empirical P value of .002, suggesting that the P value for this phenotype remains significant after adjusting for multiple testing.
Discussion
Herein, we report the detailed investigation of early evidence of MS-related findings and dysfunction in a subset of participants in the GEMS project, a large prospective cohort study of firstdegree family members. Our major finding is that neurologically asymptomatic women deemed to be at higher risk of developing MS by our risk algorithm (GERS MS ) exhibited a greater burden of potential neurological dysfunction than women at lower risk, with impaired vibration perception in the distal lower extremities being the most pronounced result. In addition, 8% (5 of 65) of all the women studied in detail met the primary neuroimaging outcome of having brain T2-weighted hyperintense lesions consistent with the 2010 McDonald MRI criteria for DIS, higher than one would expect to find in the general population. The presence of these findings and of other MS-type changes, including central veins in T2-weighted hyperintense lesions, focal leptomeningeal enhancement, and a spinal cord lesion, suggests that a subset of family members have an asymptomatic disease process and deserve further monitoring. Below, we discuss our findings in the context of prior literature, speculate on their broader significance, and mention the limitations of the present study. The intriguing neuroimaging findings from this study are consistent with prior reports A, The x-axis shows the higher-risk and lower-risk subgroups according to the Genetic and Environmental Risk Score for Multiple Sclerosis Susceptibility (GERS MS ), namely, women with GERS MS at the top 10% (High) and bottom 10% (Low). The y-axis shows vibration sensitivity in vibration units (vu), which are the amplitudes of vibration and are proportional to the square of applied voltage. The vibration sensitivity threshold was quantified separately in the left and right great toe, and an average measure was calculated. A higher vu value indicates higher threshold for detecting vibration and thus worse vibration sensitivity. The P value represents the univariate comparison between the higher-risk and lower-risk subgroups. B, A participant with the highest GERS MS in the study, who was subsequently diagnosed as having MS after the detailed testing, is shown in the larger orange bubble. The x-axis shows the vibration sensitivity as the average measurement of both great toes. The y-axis shows the vibration sensitivity as the measurement from the worse side. The 2 Vibratron II (Physitemp Instruments, Inc) measurements do not perfectly correlate in this participant. Higher-risk women are shown in the orange bubbles. Lower-risk women are shown in the blue bubbles.
concerning the frequency of MS-like white matter lesions on brain MRI among asymptomatic first-degree relatives (ranging from 4%-10%) 19 and the frequency of RIS among healthy family members (3%). 18 There were substantial differences in study design, population characteristics, MRI protocol, and predefined outcomes between our study and these earlier studies.
Determining the optimal management of first-degree relatives with MS-type findings was not our aim; an ongoing RIS trial 34 should provide information to guide treatment decisions. Our results further point to a possible sequence of events leading to MS, in which changes in vibration sensitivity may precede the appearance of demyelinating lesions in the brain. Such changes could derive from focal lesions in the dorsal columns of the spinal cord, but we cannot rule out the possibility of abnormal myelin structure or early degeneration of long axonal tracts or subcortical structures, such as the thalami. Regardless of etiology, our results underscore the importance of using sensitive tools to detect subtle neurological changes early in the MS disease process.
Our results also suggest that the present study was underpowered to detect a difference in neuroimaging outcomes between higher-risk and lower-risk women. Because, to our knowledge, the GEMS project is the first prospective study of populations at risk for MS and because this investigation is the first detailed crosssectional examination of higher-risk and lower-risk family members to date, there was limited information regarding the sample size required to detect early or subtle evidence of MS when we launched the GEMS project in 2010. The sample size calculation for the primary brain MRI outcome was initially estimated by extrapolating results from people with MS and healthy control individuals. 35 Because of the limited information available for power calculation, we planned to investigate 100 participants for this study. In retrospect, given our observations, we had excellent statistical power (99%) to detect a difference in vibration sensitivity but modest power (12%) to detect a difference in the primary MRI outcome of having brain lesions consistent with the 2010 McDonald MRI criteria for DIS (eTable 4 in the Supplement). Based on the primary neuroimaging outcome (Table 1 and eTable 5intheSupplement), we can estimate that a study comparing 283 higher-risk and 283 lower-risk female participants will be needed to attain statistical significance. Therefore, these family members with carefully characterized baseline phenotypes provide crucial insights for the future direction of the GEMS project and other similar studies. Specifically, we plan to confirm the finding of change in vibration sensitivity with a follow-up study.
Limitations
Our findings have several limitations. First, we restricted analyses to women because inclusion of sex in the individualized risk score for MS susceptibility resulted in unequal representation of women in the 2 groups. The excess of women participating in the overall GEMS project was consistent with the sex discrepancy in clinical study participation, possibly heightened by public understanding of the increased risk of MS among women. 6 We are working to increase men's participation in the GEMS project. Second, the cross-sectional assessment does not allow for definitive conclusions regarding the sequence of events over time. To address this issue, we plan to perform longitudinal assessment in individuals in whom we have baseline measurements. Third, vibration sensitivity thresholds, as quantified by a vibration sensitivity testing device, were generally within the normal range (as presented in the package insert of the device) for both risk groups. Large-scale normative data relevant to the demographics of the study population were unavailable when this study was performed. As such, we have begun to quantify vibration sensitivity in healthy volunteers. Fourth, we selected a slightly older cohort of participants for this study (mean age, 35.1 years) because we initially aimed to identify participants with RIS. With findings from this study that inform the risk model, we plan to pursue a prospective investigation in younger individuals in part to determine the mean age at which RIS develops. Fifth, we selected the qualitative and quantitative clinical and neuroimaging measures that were deployed in this study primarily based on their usefulness in studies of patients with MS and healthy controls. Although we expected low sensitivity in detecting early evidence of MS in neurologically asymptomatic first-degree family members using these measures, they inform important baseline information in the larger prospective study. Therefore, our study highlights the important need to develop and test more sensitive measures, particularly with biometric devices, to detect subtle subclinical changes early in the disease process.
Conclusions
Higher-risk asymptomatic family members of people with MS are more likely to have early subclinical manifestations of MS. Findings from this prospective cohort study underscore the importance of early detection in individuals at higher risk for MS. This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods. Supplementary Methods
Cohort Data Collection
The Genes and Environment in Multiple Sclerosis (GEMS) Study did not include participants older than 50, as the mean age at MS diagnosis is in the early thirties and the age-related appearance of nonspecific white matter lesions in older individuals could confound neuroimaging outcomes. The GEMS study has been recruiting participants from across the United States. As of September 2016, the study has enrolled 2687 participants with representation from every state.
Upon enrollment, each GEMS participant completes a detailed web-based questionnaire that captures demographics, medical history, family history, and environmental exposures. Each participant mails a saliva sample for extraction of DNA (OG-500 DNA Genotek, Ontario, Canada). Participants are asked to complete additional questionnaires annually and donate biological samples (blood, stool) with the goal to follow each for 20 years 1 . The institutional review boards of Partners Health, National Institute of Health, and University of Pittsburgh approved the study.
Individualized Risk Estimate and Stratification
Genotyping of MS risk variants and calculation of the Genetic and Environmental Risk Score for Multiple Sclerosis Susceptibility (GERS MS ) in GEMS participants have been previously described 1 . In brief, a list of 64 single nucleotide polymorphisms (SNPs) that are significantly associated with the risk of developing MS based on published genome-wide association studies of MS susceptibility [2] [3] [4] , including five within the major histocompatibility complex (MHC) region, was the most up-to-date as of 2012 when targeted genotyping of GEMS participants first began. Each SNP was coded additively by the established risk allele and weighted by the natural log of the published odds ratio for MS susceptibility. For the validated non-genetic risk factors, we counted the presence or absence of the factor, each weighted by the natural log of a published odds or risk ratio: sex (which confers different hormonal milieu between women and men) 5 , infectious mononucleosis 6 , current smoking status 7 . For each participant with completed genotype and questionnaire data, we calculated a weighted GERS MS , a summary estimate of one's risk for MS that incorporates genetic burden and environmental exposure history. GERS MS was analyzed as both continuous and categorical variables.
Study Location and Subject Selection for Deep Phenotyping
Between August 2012 and July 2015, one hundred neurologically asymptomatic participants in the GEMS cohort of first-degree family members traveled from various locations across the United States to NIH in Bethesda, MD, for detailed neuroimaging, laboratory, and neurological examination.
Participants were selected for detailed study based on their risk profile for MS susceptibility. The original plan was to examine equal numbers of participants with GERS MS at the top 10% and the bottom 10% of the GEMS cohort. Due to the variable availability of the participants and the complexity of travel arrangements, the final ratio of the higher and lower risk participants was non-uniform, ultimately reaching a ratio of approximately 3:2 (Supplementary Table 1 ). Given that 96% of the participants in the overall GEMS study are of non-Hispanic European descent 1 , we focused this phase of the study exclusively on non-Hispanic European descent to mitigate confounding due to inter-individual variability resulting from race and ethnicity. Inclusion of small numbers of minorities would potentially diminish the statistical power and would not allow a meaningful subset analysis of the minority population. We excluded participants with an existing diagnosis of MS or other significant central nervous system (CNS) diseases (e.g., neoplasm, cerebrovascular disease, neurodegenerative disease, or known CNS inflammatory disease) or any contraindications to MRI.
Biological Sample Collection
During the NIH visit, participants donated blood and saliva samples that have been banked. Total 25-hydroxy Vitamin D (25-OH Vit D) level was measured using a chemiluminescent immunoassay (DiaSorin Liaison XL: Stillwater, MN). Additional assays using biological samples will be reported separately in the future.
Standard Neurological Examination
Board-certified neurologists and experienced nurse practitioners with specialty training in MS performed the standard neurological examination, including the 128 Hz tuning fork test. As part of the exam, we recorded the Expanded Disability Status Scale (EDSS) score 8 .
Quantitative Neurological Evaluation Trained research assistants obtained the following quantitative clinical measures: (1) MS Functional Composite (MSFC)
9 , which includes the Timed 25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (PASAT); (2) the written form of the Symbol-Digit Modalities Test (SDMT) 10, 11 ; (3) Timed Up-and-Go (TUG) 12, 13 , (4) vibration sensitivity measured using two additional modalities in addition to the 128 Hz tuning fork (see below).
We performed quantitative assessment of the vibration sensitivity at the proximal interphalangeal joint of the great toe on both sides using three modalities: (1) 128 Hz tuning fork, (2) Rydel-Seiffert graduated tuning fork 14, 15 , and (3) Vibratron-II device [16] [17] [18] [19] . For the 128 Hz tuning fork test, administered as part of the standard neurological exam, the vibration disappearance threshold was documented as the total elapsed time until a participant ceased to experience vibration. The duration was reported as a binary variable of either ≤25 seconds or >25 seconds. For the Rydel-Seiffert test, the vibration disappearance threshold was reported as the intersection of two virtual triangles that move on a scale from 0 to 8. For the Vibratron-II device, vibration sensation thresholds (vibration units) were quantified as previously reported in studies of MS patients [17] [18] [19] . Briefly, frequency is held constant while the examiner controls the applied amplitude and the sequence of intensities for each rod. For each trial, vibration stimulation was present in one of the two rods, and the participant was asked to report which rod was vibrating.
The same Vibratron-II device was used throughout the course of this study for all GEMS participants as well as 14 healthy women volunteers from a different study. The device remained intentionally uncalibrated during the study period to avoid amplifying batch effect. In a linear regression model, the average vibration sensitivity threshold in women from the GEMS study, as detected by Vibratron-II, drifted lower during the study period (beta-coefficient=-0.011, p=0.0024). This trend is primarily due to the original goal of having equal ratio of higher-and lower-risk participants and the complexity of making travel arrangement of the GEMS study participants, such that more higher-risk women completed the study visit during the first half of the study period whereas more lower-risk women completed the study during the second half of the study period. More important, the average vibration sensitivity measure in healthy women during the overlapping period was not influenced by test date (beta-coefficient=0.0068, p=0.64). This points to the absence of substantial intrinsic drift in Vibratron-II measurement over time.
Visual Function Testing
Trained research assistants administered the monocular and binocular letter acuity test using retro-illuminated high-and low-contrast Sloan letter charts (100% and 1.25% contrast levels at 2 meters, Precision Vision, LaSalle, IL). Participants were asked to wear their usual distance glasses or contact lenses if applicable. Participants read off the letters from three charts. For each chart, we recorded the number of correctly identified letters (out of maximum score of 60 per chart).
Optical Coherence Tomography (OCT)
We performed OCT in both eyes using the Spectralis device (Heidelberg Engineering, Inc., Heidelberg, Germany). Retinal nerve fiber layer (RNFL) measures were acquired as described elsewhere 20 . Briefly, these scan protocols provided the mean RNFL thickness for 360 degrees around the optic disc (12 deg diameter circle scan, 100-ART) and total macular volumes (20x20 deg, 49 cross-sectional or B-scans, 16-ART). All scans passed quality control. Qualitative assessment did not reveal gross macular pathology in the study participants.
Brain Magnetic Resonance Imaging (MRI)
Image Acquisition: Participants underwent brain MRI scans on a 3-tesla (T) wholebody MR system (Skyra; Siemens; Erlangen, Germany), equipped with a 32-channel phased array receiver head coil and gradient coils. The MRI protocol included the following sequences: 3D isotropic volumetric T1-weighted MPRAGE, 3D-T2-weighted fluid-attenuated inversion recovery or FLAIR (1 mm isotropic), and 3D-segmented echo planar imaging T2*-weighted (0.65 mm isotropic). During imaging, a single dose (0.1 mmol/kg) of gadobutrol (Gadavist) was injected using a power injector (Medrad, Warrendale, PA) at a speed of 1 ml/second to assess for the presence of enhancing MS lesions. Due to technical difficulties with the power injector and scan time constraints, one out of 100 participants did not receive gadobutrol.
Image Processing: The images collected directly from the MR imager underwent post-processing through an automated pipeline that was built in-house using the Nipype data processing framework 21 . To correct for motion between acquisitions, a rigid registration was performed between different image volumes with normalized mutual information as the cost function and windowed sinc interpolation. All scans were also rigidly aligned to the Montreal Neurological Institute (MNI152) structural atlas 22 to provide a rough spatial alignment between participants and hence a regularized visual appearance. A FLAIR* volume 23 for perivenous lesion detection was calculated by the voxel-wise multiplication of the co-registered T2*-weighted and FLAIR volumes.
Image Analysis: For lesion analysis, the primary outcome was the presence or absence of hyperintense lesions on T2-weighted FLAIR sequences (for the upper cervical spinal cord, T1-weighted MPRAGE sequences). Two experienced reviewers (D.S.R., an attending neuroradiologist with 11 years of experience in MS imaging, and M.K.S., a neurologist with 5 years of experience in neurology and 2 years of subspecialty fellowship training in MS) evaluated all scans for the presence, appearance, and location of lesions, as well as the presence of absence of leptomeningeal enhancement 24 , using standard radiology viewing software (Carestream Vue, Rochester, NY). In addition, lesions were analyzed for perivenous appearance 25, 26 . A finding on brain MRI was defined as a "lesion" if it met the following three criteria: (1) ovoid, well-circumscribed, and homogeneous focus with or without involvement of the corpus callosum, (2) a T2 hyperintensity measuring >3mm, and (3) not consistent with a vascular pattern 27 . The two reviewers reviewed all scans in a blinded fashion without prior access to a participant's risk profile.
For volumetric analysis, the Lesion-TOADS (Topology-Preserving Anatomical Segmentation) method was deployed as previously described 28 . Briefly, this technique segments the brain into its component substructures while simultaneously delineating MS lesions, yielding volumes of the following regions of interest: cortical gray matter, cerebral white matter, cerebrospinal fluid, and thalamus. Images underwent nonparametric, non-uniform intensity normalization inhomogeneity correction and skull stripping before segmentation 29 . Raw volumes were normalized to intracranial volume. Brain parenchymal fraction (BPF) was calculated as total brain volume divided by intracranial volume. Spinal cord cross-sectional area, from the C1-C2 intervertebral disc level to the C5 vertebral body level, was derived from the 3D T1-weighted MPRAGE sequences using a semi-automatic algorithm based on edge detection 30 and a mean upper cervical spinal cord cross-sectional area was calculated.
Additional Statistical Analysis
In an omnibus test (Fig. 1B) , we tested the hypothesis that the chi-squared statistic as calculated from a Fisher's combined probability test (combining the p-values of phenotypes) was higher in the observed data than expect by chance. To generate an empirical distribution of chi-squared statistics, we performed 10,000 permutations. For each permutation, we randomly assigned data to GERS MS risk category, maintaining the number of cases per category. We then evaluated each phenotype for association with risk group, and finally combined the resulting p-values using Fisher's combined probability test. Because we permuted the risk group and not the phenotype, the correlation structure of the phenotypes was maintained within each permutation. The omnibus p-value was the number of times we saw a chi-squared statistic in the empirical distribution that was greater than the observed chi-squared statistic, divided by the number of permutations (10,000). A quantile-quantile (qq)-plot was generated by plotting the observed p-value (-log10 [p-value]) for all measures against the expected p-value (-log10 [p-value]) with the assumption that there was no difference between higher and lower risk participants (i.e., null hypothesis). To create confidence intervals for the qqplot, we used the extreme ranges (90% and 95%) of the randomly generated p-values.
To create a composite categorical trait in which there was an abnormal finding on at least one of the measured outcomes (brain MRI, OCT, or clinical), we included all dichotomous outcomes and continuous outcomes. For dichotomous outcomes, an abnormal finding was defined as meeting the criterion for abnormality. For continuous outcomes, the threshold for abnormality was set at one, two, or three standard deviations away from the mean of the study population toward the expected direction of abnormality. A participant was categorized as meeting the composite outcome if any one of the measured outcomes was abnormal.
eResults. Supplementary Results
We assessed the proportion of participants having an abnormal finding on at least one of the measured outcomes (brain MRI, OCT, or neurological exam). To identify outliers, we set the threshold at three standard deviations away from the mean in the direction of abnormal finding for a continuous trait or meeting the abnormal criterion for a dichotomous trait. Among the women who completed the entire battery of tests (including vibration sensitivity testing), we did not observe a statistically significant difference between higher and lower risk women (eTable 3), possibly due to the large variance for this composite categorical trait and the modest sample size. However, there was a suggestion of a greater proportion of higher-risk women to be outliers. Interestingly, 30% of the women who underwent the entire battery of testing (including vibration sensitivity) exhibited at least one abnormal finding as defined above (eTable 3).
Comparisons between the higher and lower risk group for the primary neuroimaging outcome (proportion of participants meeting the 2010 McDonald criteria for dissemination in space, Table 1 ) and the vibration sensitivity measure (the average of the measurement in the right and left great toe, Table 2 ) for the entire study cohort, without restriction to women, are shown in eTable 5. We note that these comparisons should not be construed as statistically meaningful due to the extremely skewed distribution of sex between the higher and lower risk groups A participant was defined as having any anomaly if the participant had at least one abnormal finding on any of the measured phenotypes brain magnetic resonance imaging scan (Table 2) , optical coherence tomography (Table 2) , or quantitative neurological exam (Table 2) , including vibratron measure (Table 3) . For a given dichotomous outcome, an abnormal finding was the presence thereof. For a given continuous outcome, an abnormal finding was defined as having greater than one, two, or three standard deviations away from the mean of the study population in the expected direction of the abnormality. We did not observe any statistically significant difference between higher and lower risk women, possibly due to the large variance for this composite categorical trait and the modest sample size.
Percentage of the number of participants in the column A. Meeting the criterion for abnormality for a dichotomous trait or having one standard deviation away from the mean in the expected direction of the abnormality for a continuous trait.
B. Meeting the criterion for abnormality for a dichotomous trait or having two standard deviations away from the mean in the expected direction of the abnormality for a continuous trait. C. Meeting the criterion for abnormality for a dichotomous trait or having three standard deviations away from the mean in the expected direction of the abnormality for a continuous trait. Abbreviations: (A) Spearman's rank correlation coefficients (rho) between a given pair of phenotypes are shown on a color scale from -1 to 1. The size of each bubble indicates the significance level of the correlation. (B) The measured outcomes are ordered in a hierarchical clustering graph using average linkage. The distance measure used for the graph is the correlation distance. For a given outcome, the expected direction (green) indicates that a greater proportion of higher risk participants exhibited abnormality than the lower risk participants, whereas unexpected direction (red) indicates the opposite.
